Information for Physicians

Thank you for considering the The Assessment of Prednisone in Remission (TAPIR) Trial.

Your patient has recently approached you about their participation in this trial.

What you need to know:

  • This trial is being conducted by Peter Merkel, MD, director of the Vasculitis Clinical Research Consortium; and funded under the National Heart Lung and Blood Institute.

  • You do not need IRB approval.

    The US Government Office for Human Research Protections (OHRP) and the University of South Florida IRB agree that as this patient's treating physician, you are not engaged in research for this trial design. All patients will be consented electronically by the University of South Florida. (USF IRB# Pro00013241)

  • Your patient remains under your care.

  • You, as this patient's treating physician, may modify their prednisone dose as clinically indicated during the trial.

  • This trial will evaluate if clinical research can be conducted in a community setting.

Goals of this trial:

  • This trial will assess the effects of tapering prednisone doses to either 5 mg or 0 mg per day in patients with granulomatosis with polyangiitis (GPA, Wegener's), who are in remission.

  • This trial will evaluate the ability to conduct clinical research in a community setting as compared to traditional clinical research conducted in a research university setting. The results of this trial will be compared with a parallel trial conducted through traditional Vasculitis Clinical Research Consortium centers.

  • This trial will evaluate the role of social media and the efficacy of using online methods for recruitment and consenting to overcome limitations of traditional subject recruitment and enrollment through university clinical research centers.

Your patient will follow your instructions

  • Your patient will follow your instructions for tapering to their randomized dose.

  • We respect your expertise as this patient's provider to know what is in their best interest. If your patient's randomization assignment conflicts with the standard of care you would prescribe for this patient, he/she will be ineligible to participate.

Get more detailed information about this trial:

Contact Us:

If you have any questions please contact the trial coordinator at or 1-888-443-1793

Download the facts about this trial:


Ready to join TAPIR?

  • For patients with diagnosed GPA
  • Participate from anywhere - online!
  • Must currently be in remission
  • Continue to see your own doctor

*other conditions may apply. Learn more

Questions Contact our Study Coordinator